A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Phase of Trial: Phase III
Latest Information Update: 24 May 2016
Price : $35 *
At a glance
- Drugs Dasotraline (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Sunovion Pharmaceuticals
- 10 May 2016 Status changed from active, no longer recruiting to completed.
- 08 Apr 2015 Planned number of patients changed from 600 to 700, as reported by ClinicalTrials.gov.
- 08 Apr 2015 Planned End Date changed from 1 Oct 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.